Lumed
Lumed, founded in 2012 in Sherbrooke, Canada, develops clinical decision support systems for hospitals, including antimicrobial stewardship (APSS), infection surveillance (ZINC), and oncology (ONCO) software. A bioMérieux subsidiary since 2017, it distributes globally.
- Company typePrivate
- Founded2012
- HeadquartersSherbrooke, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Lumed does
Lumed is a Canadian healthcare software company headquartered in Sherbrooke, Quebec, founded in 2012 by three Université de Sherbrooke researchers (Vincent Nault, Louis Valiquette, and Mathieu Beaudoin) to commercialize academic work on optimizing antibiotic treatments and reducing hospital costs. The company develops clinical decision support software for hospitals across three high-impact clinical domains: antimicrobial prescription optimization (APSS), infection surveillance and outbreak detection (ZINC), and chemotherapy protocol management (ONCO), supported by a DATA analytics and reporting module. Since October 2017, Lumed has operated as a wholly-owned subsidiary of bioMérieux following the French in vitro diagnostics leader's strategic equity investment.
Lumed's product suite combines rule-based expert systems with structured clinical data integration. APSS analyzes each antimicrobial prescription against patient-specific conditions (renal function, drug interactions, pharmacokinetics calculators for vancomycin and colistin, syndromic modules) and generates alert-scored recommendations to pharmacists, with a published demonstration of 20%+ sustained reduction in antimicrobial use over three years and $2.1M CAD in antimicrobial purchase savings over six years at Centre Hospitalier Universitaire de Sherbrooke. ZINC monitors more than twenty hospital-associated infections in real time, including multi-resistant pathogen recognition and outbreak tracking. ONCO provides electronic chemotherapy prescribing with automated dose calculators, validation rules tied to lab results, and reusable protocol blocks; an FMECA study at CIUSSS de l'Estrie - CHUS measured a 51% reduction in chemotherapy prescription risks versus paper workflows. APSS holds a CE Mark as a certified medical device in Europe. Mathematics-led R&D under Beaudoin (PhD in AI from Université de Sherbrooke) was externally validated when the APSS AI work received the Deployed Innovative Application Award at the IAAI international conference.
Lumed operates a B2B enterprise software model with quote-based subscription licensing for APSS, ZINC, ONCO, and the DATA module, sold to hospital pharmacy directors, infection prevention teams, and oncology leadership. Distribution is dual-channel: direct enterprise engagement (demos and technical specifications via the website) and global distribution of APSS/DATA through bioMérieux's commercial organization across Europe, Canada, and the United States. Named customers include Centre Hospitalier Universitaire de Sherbrooke and CIUSSS de l'Estrie - CHUS, both within the same Sherbrooke-area health network. The company reports 11-50 employees, has not disclosed revenue, and functions as an R&D-intensive specialized subsidiary inside a large diagnostics parent rather than an independent venture-backed scale-up.
Lumed firmographics
Firmographics- Name
- Lumed
- Legal name
- Lumed
- Website
- https://lumed.ca
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lumed, founded in 2012 in Sherbrooke, Canada, develops clinical decision support systems for hospitals, including antimicrobial stewardship (APSS), infection surveillance (ZINC), and oncology (ONCO) software. A bioMérieux subsidiary since 2017, it distributes globally.
- Ownership category
- akta.pro rank
Lumed industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Pharmacovigilance & Drug Safety Software (HLAGAJAK)
Keywords
Where Lumed is headquartered
LocationHeadquarters
- HQ city
- Sherbrooke
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Lumed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Licensing / Subscription: Lumed generates revenue through licensing its expert system software (APSS, ZINC, ONCO, DATA) to hospitals. The software is sold as a certified medical device in Europe and deployed via enterprise agreements. As a company of bioMérieux, distribution is facilitated globally through bioMérieux's commercial organization, and pricing is handled via direct sales / quote-based engagement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise Hospital Licensing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Lumed product offering
Product offeringCore offering
Lumed develops and sells certified clinical decision support / expert-system software for hospitals, packaged as four products: APSS for antimicrobial prescription surveillance and stewardship, ZINC for real-time nosocomial infection surveillance, ONCO for chemotherapy protocol prescription and management, and a DATA analytics/reporting module. The software is sold to hospital pharmacy, infection control, and oncology teams as a CE-marked medical device in Europe, and is distributed both directly and through bioMérieux's global commercial channel.
Product overview
Lumed offers a suite of clinical decision support expert systems for hospitals consisting of three core products: APSS (antimicrobial stewardship software), ZINC (infection surveillance software), and ONCO (oncology protocol management), supported by a DATA analysis and reporting module. These systems work to optimize antimicrobial use, prevent nosocomial infections, and secure chemotherapy prescriptions in healthcare settings.
Differentiator
Problem solved
Functional benefit
Brands
- APSS+: Antimicrobial Stewardship Software - clinical decision support system for optimizing antimicrobial prescriptions
- ZINC+
- ONCO+
- DATA+
Products and services
- APSS (Antimicrobial Prescription Surveillance System) Clinical decision support software for antimicrobial stewardship that continuously analyzes antimicrobial prescriptions against patient condition, drug-pathogen match, drug interactions, and spectrum redundancy, then sends prioritized alerts to pharmacists. Includes pharmacokinetics calculators for vancomycin and colistin, syndromic approach modules, and real-time patient monitoring with alert scoring. CE-marked as a medical device in Europe; targets hospital antimicrobial stewardship programs.
- ZINC (Infection Surveillance Software) Real-time infection surveillance software that identifies and tracks positive cases for more than twenty healthcare-associated infections, recognizes multi-resistant pathogens from antibiogram results, supports outbreak detection and patient tracking, manages isolation, and provides inquiry-form documentation tools. Used by hospital infection prevention and control teams.
- ONCO (Oncology Protocol Prescription and Management Software) Electronic chemotherapy prescription and oncology protocol management software that organizes patient clinical data, provides dose calculators, applies validation rules based on patient demographics and lab results, structures medical notes for oncology, supports reusable protocol blocks, and includes a custom reporting module. Used by oncologists, hematologists, oncology pharmacists, and oncology nurses.
- DATA (Analysis Module) Reporting and analytics module that combines with ZINC and other Lumed products to produce nosocomial infection incidence reports, isolation day counts by infection type, antimicrobial consumption reports, bacterial resistance evolution reports, and custom hospital statistics to support decision-making and regulatory reporting.
Quantifiable outcome
- 20%+ reduction in antimicrobial use over 3 years (Nault V et al, J Antimicrob Chemother. 2017)
- +4 more outcomes
Companies that use Lumed
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Lumed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Lumed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- bioMérieuxflagshipLumed was acquired by bioMérieux in October 2017. bioMérieux, a world leader in in vitro diagnostics, invested in Lumed as a strategic investor and provides global commercial distribution for Lumed's APSS and DATA software in Europe, Canada, and the United States. The synergy between bioMérieux's diagnostic data and Lumed's clinical decision algorithms enables optimized antimicrobial prescriptions for each hospitalized patient. This investment completed a funding round that also included ACET Capital, Bank of Development of Canada, Desjardins, Economic Development Canada, and Can-Export.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Lumed competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Lumed social profiles
Digital presenceLumed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lumed leadership team
Management profileNumber of profiles
Profiles3 records
Lumed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lumed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lumed
What does Lumed do?
Lumed develops and sells certified clinical decision support / expert-system software for hospitals, packaged as four products: APSS for antimicrobial prescription surveillance and stewardship, ZINC for real-time nosocomial infection surveillance, ONCO for chemotherapy protocol prescription and management, and a DATA analytics/reporting module. The software is sold to hospital pharmacy, infection control, and oncology teams as a CE-marked medical device in Europe, and is distributed both directly and through bioMérieux's global commercial channel.
Is Lumed a public or private company?
Lumed is a private company. It is classified as corporate owned and is currently operating.
When was Lumed founded?
Lumed was founded in 2012. It employs 11 to 50 people.
Where is Lumed based?
Lumed is headquartered in Sherbrooke, Canada, in the North America region.
How does Lumed make money?
One revenue line is on record: software Licensing / Subscription.
Does Lumed have an API?
No public API is recorded for Lumed.
What industry is Lumed in?
Lumed's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 513210 and its SIC code is 8000.